Trial Profile
Open Label, Randomised Exploratory Dose Response Study in Pharmacodynamics and Safety of BIBR 1048 (110 mg b.i.d. and 150 mg b.i.d.) for 12 Weeks in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Myocardial infarction; Stroke; Thromboembolism; Transient ischaemic attacks
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 05 Jun 2010 New trial record